Vascular effects of rapid-acting insulin analogs in the diabetic patient

A review

Steve Fordan, Philip Raskin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting insulins to treat diabetes. We review the evidence for treating hyperglycemia, using insulin, and specifically using rapid-acting analogs in diabetic individuals, on the prevention of vascular events. We review the beneficial effects of insulin on the vascular system, which include vasodilation and anti-inflammatory actions. The effects of treating hyperglycemia and intensive blood glucose control on vascular outcomes are reviewed.

Original languageEnglish (US)
Pages (from-to)225-231
Number of pages7
JournalVascular Health and Risk Management
Volume5
StatePublished - 2009

Fingerprint

Short-Acting Insulin
Blood Vessels
Hyperglycemia
Insulin Lispro
Insulin
Vasodilation
Blood Glucose
Anti-Inflammatory Agents

Keywords

  • Aspart
  • Glulisine
  • Lispro
  • Nitric oxide synthetase
  • Nuclear factor kappa B

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

Vascular effects of rapid-acting insulin analogs in the diabetic patient : A review. / Fordan, Steve; Raskin, Philip.

In: Vascular Health and Risk Management, Vol. 5, 2009, p. 225-231.

Research output: Contribution to journalArticle

@article{1dfe9498a1474fe686e5be6d15dca8b9,
title = "Vascular effects of rapid-acting insulin analogs in the diabetic patient: A review",
abstract = "The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting insulins to treat diabetes. We review the evidence for treating hyperglycemia, using insulin, and specifically using rapid-acting analogs in diabetic individuals, on the prevention of vascular events. We review the beneficial effects of insulin on the vascular system, which include vasodilation and anti-inflammatory actions. The effects of treating hyperglycemia and intensive blood glucose control on vascular outcomes are reviewed.",
keywords = "Aspart, Glulisine, Lispro, Nitric oxide synthetase, Nuclear factor kappa B",
author = "Steve Fordan and Philip Raskin",
year = "2009",
language = "English (US)",
volume = "5",
pages = "225--231",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Vascular effects of rapid-acting insulin analogs in the diabetic patient

T2 - A review

AU - Fordan, Steve

AU - Raskin, Philip

PY - 2009

Y1 - 2009

N2 - The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting insulins to treat diabetes. We review the evidence for treating hyperglycemia, using insulin, and specifically using rapid-acting analogs in diabetic individuals, on the prevention of vascular events. We review the beneficial effects of insulin on the vascular system, which include vasodilation and anti-inflammatory actions. The effects of treating hyperglycemia and intensive blood glucose control on vascular outcomes are reviewed.

AB - The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting insulins to treat diabetes. We review the evidence for treating hyperglycemia, using insulin, and specifically using rapid-acting analogs in diabetic individuals, on the prevention of vascular events. We review the beneficial effects of insulin on the vascular system, which include vasodilation and anti-inflammatory actions. The effects of treating hyperglycemia and intensive blood glucose control on vascular outcomes are reviewed.

KW - Aspart

KW - Glulisine

KW - Lispro

KW - Nitric oxide synthetase

KW - Nuclear factor kappa B

UR - http://www.scopus.com/inward/record.url?scp=67449084389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449084389&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 225

EP - 231

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

ER -